Rezolute Inc (RZLT)

Currency in USD
5.690
-0.170(-2.90%)
Closed·
After Hours
5.870+0.180(+3.16%)
·
RZLT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RZLT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.5505.850
52 wk Range
2.2156.645
Key Statistics
Prev. Close
5.69
Open
5.85
Day's Range
5.55-5.85
52 wk Range
2.215-6.645
Volume
586.38K
Average Volume (3m)
1.08M
1-Year Change
32.33%
Book Value / Share
1.36
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RZLT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.111
Upside
+130.42%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Rezolute Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Rezolute Inc Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Rezolute Inc SWOT Analysis


Pipeline Progress
Explore Rezolute's promising clinical trials for ersodetug in hyperinsulinism and RZ402 for diabetic macular edema, with key results expected in 2025-2026.
Financial Strength
Delve into Rezolute's robust financial position, with $118 million in cash and a strong current ratio, supporting ongoing clinical programs.
Market Opportunities
Learn about Rezolute's potential in niche markets, including congenital hyperinsulinism and diabetic macular edema, with oral administration as a key advantage.
Analyst Outlook
Discover varied analyst perspectives on Rezolute, with price targets ranging from $7 to $9, reflecting the company's growth potential in metabolic diseases.
Read full SWOT analysis

Compare RZLT to Peers and Sector

Metrics to compare
RZLT
Peers
Sector
Relationship
P/E Ratio
−6.8x−4.3x−0.5x
PEG Ratio
−3.70−0.170.00
Price/Book
6.0x2.5x2.6x
Price / LTM Sales
-297.8x3.3x
Upside (Analyst Target)
128.5%172.0%43.5%
Fair Value Upside
Unlock−0.2%6.9%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.111
(+130.42% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.27 / -0.24
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

RZLT Income Statement

People Also Watch

174.39
ALAB
+28.66%
38.47
BMNR
+15.53%
5.340
ATYR
+2.30%
4.36
CMPS
-2.68%
18.30
BEAM
-2.14%

FAQ

What Stock Exchange Does Rezolute Trade On?

Rezolute is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Rezolute?

The stock symbol for Rezolute is "RZLT."

What Is the Rezolute Market Cap?

As of today, Rezolute market cap is 495.01M.

What Is Rezolute's Earnings Per Share (TTM)?

The Rezolute EPS (TTM) is -1.11.

When Is the Next Rezolute Earnings Date?

Rezolute will release its next earnings report on 10 Sept 2025.

From a Technical Analysis Perspective, Is RZLT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Rezolute Stock Split?

Rezolute has split 3 times.

How Many Employees Does Rezolute Have?

Rezolute has 68 employees.

What is the current trading status of Rezolute (RZLT)?

As of 07 Aug 2025, Rezolute (RZLT) is trading at a price of 5.69, with a previous close of 5.69. The stock has fluctuated within a day range of 5.55 to 5.85, while its 52-week range spans from 2.22 to 6.65.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.